| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | NaN | 67,482 | NaN | NaN |
| Total operating expenses | NaN | 371,113 | NaN | NaN |
| Interest and other income, net | NaN | 26,774 | NaN | NaN |
| Interest expense | NaN | 1,512 | NaN | NaN |
| Income tax expense | NaN | 297 | NaN | NaN |
| Net loss | -73,333 | -80,999 | -74,116 | -123,551 |
| Share-based compensation expense | 8,416 | 11,352 | 10,965 | 14,791 |
| Accounts payable and accrued expenses | NaN | NaN | 12,716 | 2,098 |
| Amortization of premium and accretion of discounts on short-term investments, net | 900 | 1,382 | 1,924 | 5,182 |
| Depreciation expense | 355 | 403 | 164 | 465 |
| Non-cash interest expense | 106 | 103 | 141 | 271 |
| Accounts receivable, net | 544 | 6,744 | NaN | NaN |
| Receivable from contracts with collaborators | NaN | NaN | 31,362 | 2,514 |
| Inventory | 430 | 413 | NaN | NaN |
| Prepaid expenses and other current assets | 562 | -2,890 | 10,289 | 8,551 |
| Operating lease right-of-use and other long-term assets | -689 | 558 | 2,883 | 2,922 |
| Accounts payable | 2,026 | 4,499 | NaN | NaN |
| Accrued expenses and other current liabilities | -16,216 | 12,654 | NaN | NaN |
| Operating lease liabilities | 3,778 | NaN | NaN | NaN |
| Other long-term liabilities | 204 | 118 | 297 | 628 |
| Contract liabilities | -9,443 | 156,288 | 15,664 | 23,763 |
| Net cash used in operating activities | -85,854 | 117,273 | -80,627 | -100,704 |
| Purchases of short-term investments | 171,601 | 239,775 | 138,499 | 383,314 |
| Maturities of short-term investments | 147,498 | 177,500 | 235,032 | 342,596 |
| Purchases of property and equipment | 128 | 2,321 | 2,567 | 1,750 |
| Net cash used in investing activities | -24,231 | -64,596 | 93,966 | -42,468 |
| Proceeds from issuance of stock under equity plans | 69 | 1,135 | 0 | 658 |
| Proceeds from issuances of common stock and pre-funded warrants, net of offering costs | NaN | 0 | NaN | NaN |
| Net cash provided by financing activities | 69 | 1,135 | 0 | 658 |
| Net decrease in cash and cash equivalents | -110,016 | 53,812 | 13,339 | -142,514 |
| Cash and cash equivalents at beginning of period | 149,099 | 95,287 | 224,462 | NaN |
| Cash and cash equivalents at end of period | 39,083 | 149,099 | 95,287 | NaN |
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)